source
- Latigo Biotherapeutics plans IPO to fund phase 3 trials of non-opioid pain drug LTG-001Latigo Biotherapeutics announced it is preparing an initial public offering to raise capital for its clinical-stage, non-opioid pain management pipeline. The company highlighted its oral Nav1.8 in…
- Geopolitical uncertainty dampens UK biotech IPO outlook despite record Q2 venture fundingGeopolitical uncertainty continues to weigh on the sentiment around initial public offerings for British biotech companies, according to an industry leader speaking to Fierce. At the same time, th…